Moderna, INC Form 4 insider transactions

Stephen Hoge, President of Moderna, Inc., sold 80,575 shares of common stock on September 14, 2026.

James M Mock, Chief Financial Officer of Moderna, Inc., sold 34,836 shares of common stock on September 10, 2026 for $134.49 per share.

James M Mock, Chief Financial Officer of Moderna, Inc., reported multiple transactions in common stock on September 4, 2026.

Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported multiple transactions in common stock on September 4, 2026.

Stephen Hoge, President of Moderna, Inc., reported multiple transactions in common stock on August 27, 2026.

Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported multiple transactions in common stock on August 27, 2026.

James M Mock, Chief Financial Officer of Moderna, Inc., reported multiple transactions in common stock on August 27, 2026.

Stephane Bancel, Chief Executive Officer and a Director of Moderna, Inc., sold 499,246 shares of common stock on August 5, 2026.

Stephen Hoge, President of Moderna, Inc., sold 53,336 shares of common stock on July 15, 2026 for $67.60 per share.

Moderna Director Michael R. McDonnell reports acquisition of stock options and restricted stock units, with vesting schedules outlined.

Moderna's Chief Commercial Officer, Banque Soria Ester, reported transactions involving stock options and restricted stock units.

Moderna's Chief Financial Officer, James M. Mock, has reported transactions involving restricted stock units and common stock.

Moderna President Stephen Hoge reported transactions involving company stock, including purchases and sales, executed under a Rule 10b5-1 trading plan.

Moderna's Chief Legal Officer, Shannon Klinger, engaged in a series of stock transactions, including purchases and sales, under a Rule 10b5-1 trading plan.

Moderna's Chief Financial Officer, James M. Mock, reported transactions involving restricted stock units and common stock, including shares withheld for tax obligations.

Moderna's Chief Financial Officer, James M. Mock, has reported transactions involving the acquisition and disposition of company stock, including the settlement of restricted stock units and tax withholding.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported transactions involving the sale of company stock.

Moderna CFO James Mock acquired shares through the vesting of restricted stock units and withheld a portion to cover tax obligations.

Moderna Chief Legal Officer Shannon Klinger reported the vesting and partial sale of restricted stock units to cover tax obligations.

Moderna President Stephen Hoge acquired shares through the vesting of restricted stock units and withheld shares for tax obligations.

Director Noubar Afeyan exercised 9,263 stock options and subsequently sold the shares via Flagship Pioneering.

Moderna President Stephen Hoge executed a series of transactions involving company stock, including acquisitions and dispositions, under a pre-arranged Rule 10b5-1 trading plan.

Moderna Director David Rubenstein was granted stock options and restricted stock units as part of his annual compensation.

Moderna Director Abbas Hussain was granted 8,371 restricted stock units, vesting in May 2027 or at the next annual meeting.

Moderna Director Sandra Horning was granted stock options and restricted stock units as part of annual compensation.

Moderna Director Elizabeth Nabel was granted 8,371 restricted stock units as part of the company's equity compensation program.

Moderna Director Francois Nader was granted stock options and restricted stock units as part of annual compensation.

Moderna director Elizabeth E. Tallett was granted 8,371 restricted stock units as part of annual compensation.

Moderna, Inc. director Noubar Afeyan was granted 12,908 stock options as part of standard equity compensation.

Moderna, Inc. Director Sandra Horning acquired 16,233 shares of common stock following the vesting of restricted stock units.